Graham Ferrier

Graham Ferrier, PhD, is a global medical strategy and team lead specializing in GI oncology and melanoma at Pfizer. With a focus on advancing oncology therapy development, they have transformed GI oncology from concept to a robust franchise, particularly in colorectal cancer. Their achievements include leading the medical initiatives for the FDA approval of BREAKWATER, the first targeted therapy regimen for BRAF V600E mutant mCRC. Graham's extensive multidisciplinary background encompasses roles in scientific affairs and evaluation, as well as academic contributions to the fields of biology and biochemical ecology. Their education includes a PhD from the University of California, Los Angeles, and a Master’s from California State University, Northridge.